The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer's disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status

• Published in: Alzheimer's research & therapy 2021-02, Vol.13 (1), p.43-15, Article 43
• Main Authors: Ouk, Michael, Wu, Che-Yuan, Rabin, Jennifer S, Jackson, Aaron, Edwards, Jodi D, Ramirez, Joel, Masellis, Mario, Swartz, Richard H, Herrmann, Nathan, Lanctôt, Krista L, Black, Sandra E, Swardfager, Walter
• Format: Article
• Language: English
• Subjects: Alzheimer Disease - complications; Alzheimer Disease - drug therapy; Alzheimer Disease - genetics; Alzheimer's disease; Angiotensin Receptor Antagonists - therapeutic use; Angiotensin receptor blockers; Angiotensin-converting enzyme inhibitors; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Antihypertensives; Apolipoprotein E4 - genetics; Blood pressure; Blood-Brain Barrier; Brain research; Cognition; Cognition & reasoning; Cognitive Dysfunction - drug therapy; Cognitive Dysfunction - genetics; Dementia; Enzymes; Health risk assessment; Humans; Hypertension; Memory; Neuropsychological Tests; Older people; Variables; Variance analysis
• ISSN: 1758-9193; 1758-9193
• DOI: 10.1186/s13195-021-00778-8

The antihypertensive angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACE-Is) have similar indications and mechanisms of action, but prior work suggests divergence in their effects on cognition. Participants in the National Alzheimer's Coordinating Center database with a clinical diagnosis of dementia due to Alzheimer's disease (AD) using an ACE-I or an ARB at any visit were selected. The primary outcome was delayed recall memory on the Wechsler Memory Scale Revised - Logical Memory IIA. Other cognitive domains were explored, including attention and psychomotor processing speed (Trail Making Test [TMT]-A and Digit Symbol Substitution Test [DSST]), executive function (TMT-B), and language and semantic verbal fluency (Animal Naming, Vegetable Naming, and Boston Naming Tests). Random slopes mixed-effects models with inverse probability of treatment weighting were used, yielding rate ratios (RR) or regression coefficients (B), as appropriate to the distribution of the data. Apolipoprotein (APOE) ε4 status and blood-brain barrier (BBB) penetrance were investigated as effect modifiers. Among 1689 participants with AD, ARB use (n = 578) was associated with 9.4% slower decline in delayed recall performance over a mean follow-up of 2.28 years compared with ACE-I use (n = 1111) [RR = 1.094, p = 0.0327]; specifically, users of BBB-crossing ARBs (RR = 1.25, p = 0.002), BBB-crossing ACE-Is (RR = 1.16, p = 0.010), and non-BBB-crossing ARBs (RR = 1.20, p = 0.005) had better delayed recall performance over time compared with non-BBB-crossing ACE-I users. An interaction with APOE ε4 status (drug × APOE × time RR = 1.196, p = 0.033) emerged; ARBs were associated with better delayed recall scores over time than ACE-Is in non-carriers (RR = 1.200, p = 0.003), but not in carriers (RR = 1.003, p = 0.957). ARB use was also associated with better performance over time on the TMT-A (B = 2.023 s, p = 0.0004) and the DSST (B = 0.573 symbols, p = 0.0485), and these differences were significant among APOE ε4 non-carriers (B = 4.066 s, p = 0.0004; and B = 0.982 symbols, p = 0.0230; respectively). Some differences were seen also in language and verbal fluency among APOE ε4 non-carriers. Among APOE ε4 non-carriers with AD, ARB use was associated with greater preservation of memory and attention/psychomotor processing speed, particularly compared to ACE-Is that do not cross the blood-brain-barrier.